This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2017
  • /
  • 11
  • /
  • FDA accepts NDA for IDP 118, a topical treatment f...
Drug news

FDA accepts NDA for IDP 118, a topical treatment for plaque psoriasis.- Ortho Dermatologics/Valeant.

Read time: 1 mins
Last updated:3rd Nov 2017
Published:3rd Nov 2017
Source: Pharmawand

Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. announced that the FDA has accepted the New Drug Application (NDA) for IDP 118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018. If approved, IDP 118 will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially expanded duration of use.The most common adverse events were contact dermatitis (7.4%) and application site pain. (2.6%).

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.